Inactive Instrument

Highlights Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

End-of-day quote Nasdaq Other stock markets
- ^PTS	-

Jul. 03	Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 1000	CI
Jul. 03	Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to S&P 600 Health Care	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Protagonist Therapeutics to Join S&P SmallCap 600	Jun. 28	MT
Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control	Jun. 14	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	Mar. 26	CI
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	Mar. 18	CI
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	Mar. 11	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda	Jan. 31	DJ
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	Jan. 31	CI
Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis	Dec. 13	CI
Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib	Nov. 27	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Protagonist Therapeutics, Inc. Announces Achievement of $50 Million Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis	Nov. 01	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Protagonist Therapeutics Announces Positive Topline Results with Jnj-2113, the First and Only Oral Il-23 Receptor Antagonist Peptide in Development for Moderate-To-Severe Plaque Psoriasis	23-07-04	CI
Protagonist Reports Positive Results from Phase 1 and Pre-Clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113	23-05-12	CI
Protagonist Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the Revive Study of Rusfertide in Polycythemia Vera	23-03-15	CI
Protagonist Therapeutics, Inc. Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral Interleukin-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis	23-03-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Protagonist Therapeutics Inc Nasdaq

Equities

US74366E1029

Highlights

Filters